[68Ga]Ga-FAPI PET/CT 评估朗格汉斯细胞组织细胞增生症:与[18F]FDG PET/CT 的比较
32 例病理确诊的朗格汉斯细胞组织细胞增生症(LCH)患者在一周内先后接受[68Ga]Ga-FAPI 与[18F]FDG PET/CT 检查,比较两种示踪剂对病变器官的检出能力与显像强度。30 例活动性疾病患者中最常累及骨(27/30),[68Ga]Ga-FAPI 检出骨病变 106/106,而[18F]FDG 检出 52/106;[68Ga]Ga-FAPI 还识别出[18F]FDG 常漏诊的肝、皮肤及唾液腺受累,但未显示淋巴结受累。由于[68Ga]Ga-FAPI 敏感性更高,约 30%(10/30)患者疾病状态或亚型被重新分类。
要点
- 30 例活动性 LCH 患者中 27/30 累及骨,[68Ga]Ga-FAPI 检出骨病变 106/106 对比[18F]FDG 的 52/106。
- [68Ga]Ga-FAPI 识别出[18F]FDG 常漏诊的肝、皮肤及唾液腺受累,但淋巴结受累未被[68Ga]Ga-FAPI 显示。
- 因[68Ga]Ga-FAPI 敏感性更高,约 30%(10/30)患者疾病状态或亚型被重新分类。
核心结论
- [68Ga]Ga-FAPI PET/CT 在检测 LCH 骨病变及结外病变方面优于[18F]FDG PET/CT,为精准疾病评估和治疗计划提供有价值的工具。
研究设计与样本
- 本研究纳入 32 例病理确诊为 LCH 的患者,在一周内先后进行[68Ga]Ga-FAPI 与[18F]FDG PET/CT 检查以确定疾病范围和状态,并比较两种示踪剂对受累器官的检出能力和显像强度。
主要发现
- 32 例患者中 30 例为活动性疾病,2 例为非活动性疾病。
- 活动性疾病患者中最常受累器官为骨(27/30),[68Ga]Ga-FAPI PET/CT 检出骨病变 106/106,[18F]FDG PET/CT 检出 52/106。
- [68Ga]Ga-FAPI 还识别出肝、皮肤和唾液腺受累,而这些常被[18F]FDG 漏诊。
- 两种示踪剂均检出胸腺和垂体受累,但[68Ga]Ga-FAPI 显示更高的图像对比度和更强的诊断信心。
- 淋巴结受累未被[68Ga]Ga-FAPI 显示。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to explore the value of [68Ga]Ga‑FAPI PET/CT for the evaluation of Langerhans cell histiocytosis (LCH) in comparison with [18F]FDG PET/CT. METHODS: Thirty-two patients pathologically diagnosed with LCH were enrolled in this study. [68Ga]Ga‑FAPI and [18F]FDG PET/CT were performed within 1 week to identify disease extent and status. The detectability and intensity of the involved organs were compared between these two tracers. RESULTS: Thirty patients had active disease while two had non-active disease. In patients with active disease, the most commonly involved organ was bone (27/30), and [68Ga]Ga-FAPI PET/CT detected more osseous lesions (106/106) than [18F]FDG PET/CT (52/106). [68Ga]Ga-FAPI also identified liver, skin, and salivary gland involvement, which were often missed by [18F]FDG. Although both tracers detected thymus and pituitary gland involvement, [68Ga]Ga-FAPI demonstrated higher image contrast and more diagnostic confidence. Lymph node involvement, however, was not visualized by [68Ga]Ga-FAPI. Due to the superior sensitivity of [68Ga]Ga-FAPI, approximately 30% (10/30) of patients experienced reclassification in disease status or subtype. Furthermore, [68Ga]Ga‑FAPI appeared to be advantageous in response assessment. CONCLUSION: [68Ga]Ga-FAPI PET/CT outperforms [18F]FDG PET/CT in detecting osseous and extra-nodal lesions in LCH, providing a valuable tool for precise disease evaluation and treatment planning.
引用
- Zhang W, Wu Y, Guo L, et al. [68Ga]Ga‑FAPI PET/CT in the evaluation of Langerhans cell histiocytosis: comparison with [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2025. PMID: 39833506. doi:10.1007/s00259-025-07097-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。